MARKETING

Theranos & Its CEO Settle Stock Fraud Charges with SEC

Seven years ago, Theranos was a $9 billion dynamo seemingly on the precipice of blowing the blood testing market wide open. Today, the company and its CEO and founder, Elizabeth Holmes, are a … [Read more...]

DISTRIBUTION AGREEMENTS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Based on the early returns, the market analysts that predicted 2018 would see a slowdown in strategic Dx deal making appear to be right. But while deal volume was low on both the M&A and alliance … [Read more...]

COVERAGE

Emerging Tests: Medicare to Cover Next Gen-Sequencing Tests for Advanced Cancer

In the PAMA era, there are two salient trends in Medicare Part B lab reimbursements: Sharply lower prices for traditional tests; and Wider coverage of newly emerging tests, including some that … [Read more...]

INDUSTRY BUZZ

FDA Watch: Personalized Medicine Approvals Continue to Flow

After a slow start to the year, new product business picked up significantly in the past four weeks. Here's a rundown of the key diagnostic product launches from mid-January through late … [Read more...]

REIMBURSEMENT

Out of Network: 6 Frequently Asked Questions

By Richa Singh  bio As labs face an increasingly challenging reimbursement environment, more providers are doubling down on out-of-network strategies to maximize on collections … [Read more...]

NEW PRODUCTS

The Dx Pipeline: A Roundup of the Month’s Key New Product Launches

After a slow start to the year, new product business picked up significantly in the past four weeks. Here's a rundown of the key diagnostic product launches from mid-January through late … [Read more...]

PARTNERSHIPS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

As the calendar turned to 2018 and Medicare turned to PAMA, diagnostic deal making revved up. Deal volume was relatively heavy although short on drama. But what looks to be a big year is just … [Read more...]

ANNUAL SURVEY

Outreach Survey Focuses on Clinical Laboratory Industry Trends Amidst Greatest Disruption in Three Decades

By Jeff Myers  bio Accumen Inc. is pleased to announce the launch of the 17th Annual National Hospital and Health System Laboratory and Outreach Survey. The survey is designed to capture … [Read more...]

REVENUES

Dx Earnings Report: Strong Q4 as Lab Companies End Year with a Bang

Big PAMA cuts may lay ahead in 2017, but the diagnostics industry had a robust 2017. While the entire year was strong, success was the most widespread in the fourth quarter with all but a few … [Read more...]

FEE SCHEDULES

Industry Buzz: ACLA Goes for Kill in PAMA Lab Fees Challenge Case

Attorneys for the American Clinical Laboratory Association asked the federal court for summary judgment in its lawsuit challenging the legality of the new PAMA-based Medicare Part B fee schedule for … [Read more...]


(-0000g2)